{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:43:59Z","timestamp":1740159839721,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Comisi\u00f3n Acad\u00e9mica de Posgrado, Universidad de la Rep\u00fablica"},{"DOI":"10.13039\/501100024018","name":"Programa de Desarrollo de las Ciencias B\u00e1sicas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006049","name":"Comisi\u00f3n Sectorial de Investigaci\u00f3n Cient\u00edfica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13318-024-00901-8","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T11:01:46Z","timestamp":1718362906000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations"],"prefix":"10.1007","volume":"49","author":[{"given":"Alejandra","family":"Schiavo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Fagiolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1aki","family":"Tr\u00f3coniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-6367","authenticated-orcid":false,"given":"Manuel","family":"Ibarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"unstructured":"OECD. Health at a Glance 2015: OECD Indicators. Paris: OECD Publishing;2013.","key":"901_CR1"},{"unstructured":"OECD, The World Bank. Health at a Glance: Latin America and the Caribbean 2020. OECD Publishing. Paris: OECD Publishing;2020.","key":"901_CR2"},{"issue":"10","key":"901_CR3","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/j.xphs.2018.06.013","volume":"107","author":"R Cristofoletti","year":"2018","unstructured":"Cristofoletti R, Rowland M, Lesko LJ, Blume H, Rostami-Hodjegan A, Dressman JB. Past, present, and future of bioequivalence: improving assessment and extrapolation of therapeutic equivalence for oral drug products. J Pharm Sci. 2018;107(10):2519\u201330. https:\/\/doi.org\/10.1016\/j.xphs.2018.06.013.","journal-title":"J Pharm Sci"},{"unstructured":"FDA. Guidance for industry waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system;2000.","key":"901_CR4"},{"issue":"1","key":"901_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/cpt.1065","volume":"104","author":"L Fang","year":"2018","unstructured":"Fang L, Kim MJ, Li Z, Wang Y, DiLiberti CE, Au J, et al. Model-informed drug development and review for generic products: summary of FDA public workshop. Clin Pharmacol Ther. 2018;104(1):27\u201330. https:\/\/doi.org\/10.1002\/cpt.1065.","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"901_CR6","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1002\/cpt.1065","volume":"30","author":"A Dubois","year":"2011","unstructured":"Dubois A, Lavielle M, Gsteiger S, Pigeolet E, Mentr\u00e9 F. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm. Stat Med. 2011;30(21):2582\u2013600. https:\/\/doi.org\/10.1002\/cpt.1065.","journal-title":"Stat Med"},{"key":"901_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.216","author":"A Dubois","year":"2012","unstructured":"Dubois A, Gsteiger S, Balser S, Pigeolet E. Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling. Clin Pharmacol Ther. 2012. https:\/\/doi.org\/10.1038\/clpt.2011.216.","journal-title":"Clin Pharmacol Ther"},{"key":"901_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxaa026","author":"K M\u00f6llenhoff","year":"2020","unstructured":"M\u00f6llenhoff K, Loingeville F, Bertrand J, Nguyen TT, Sharan S, Zhao L, et al. Efficient model-based bioequivalence testing. Biostatistics. 2020. https:\/\/doi.org\/10.1093\/biostatistics\/kxaa026.","journal-title":"Biostatistics"},{"issue":"10","key":"901_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695\u2013714. https:\/\/doi.org\/10.2165\/00023210-200216100-00004.","journal-title":"CNS Drugs"},{"issue":"59","key":"901_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.seizure.2018.04.012","volume":"2018","author":"W Nasreddine","year":"2018","unstructured":"Nasreddine W, Dirani M, Atweh S, Makki A, Beydoun A. Determinants of free serum valproate concentration: a prospective study in patients on divalproex sodium monotherapy. Seizure. 2018;2018(59):24\u20137. https:\/\/doi.org\/10.1016\/j.seizure.2018.04.012.","journal-title":"Seizure"},{"issue":"1\u20132","key":"901_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0920-1211(02)00251-6","volume":"53","author":"JC Cloyd","year":"2003","unstructured":"Cloyd JC, Dutta S, Cao G, Walch JK, Collins SD, Granneman GR. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 2003;53(1\u20132):19\u201327. https:\/\/doi.org\/10.1016\/S0920-1211(02)00251-6.","journal-title":"Epilepsy Res"},{"key":"901_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/00007691-198612000-00005","volume":"8","author":"J Cramer","year":"1986","unstructured":"Cramer J, Mattson R, Bennet D, Swick C. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther Drug Monit. 1986;8:411\u20135. https:\/\/doi.org\/10.1097\/00007691-198612000-00005.","journal-title":"Ther Drug Monit"},{"unstructured":"Abbott Laboratories. Depakote ER (divalproex sodium) tablet, extended release for oral use FDA approved labeling text;2011. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021168s016lbl.pdf. Accessed 16 May 2024.","key":"901_CR13"},{"issue":"8","key":"901_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/bdd.420","volume":"25","author":"S Dutta","year":"2004","unstructured":"Dutta S, Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm Drug Dispos. 2004;25(8):345\u201352. https:\/\/doi.org\/10.1002\/bdd.420.","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"901_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijpharm.2011.11.022","volume":"423","author":"A Garc\u00eda-Arieta","year":"2012","unstructured":"Garc\u00eda-Arieta A, Morales-Alcelay S, Herranz M, De La Torre-Alvarado JM, Bl\u00e1zquez-P\u00e9rez A, Su\u00e1rez-Gea ML, et al. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products. Int J Pharm. 2012;423(2):321\u20135. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.11.022.","journal-title":"Int J Pharm"},{"issue":"2","key":"901_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jchromb.2005.11.028","volume":"830","author":"H Amini","year":"2006","unstructured":"Amini H, Javan M, Ahmadiani A. Development and validation of a sensitive assay of valproic acid in human plasma by high-performance liquid chromatography without prior derivatization. J Chromatogr B. 2006;830(2):368\u201371. https:\/\/doi.org\/10.1016\/j.jchromb.2005.11.028.","journal-title":"J Chromatogr B"},{"key":"901_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106399","volume":"183","author":"A Schiavo","year":"2023","unstructured":"Schiavo A, Maldonado C, V\u00e1zquez M, Fagiolino P, Troc\u00f3niz IF, Ibarra M. Quantitative systems pharmacology model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation. Eur J Pharm Sci. 2023;183: 106399. https:\/\/doi.org\/10.1016\/j.ejps.2023.106399.","journal-title":"Eur J Pharm Sci"},{"unstructured":"Swihart B, Lindsey J. gnlm: generalized nonlinear regression models R package;2019. Available from: https:\/\/cran.r-project.org\/web\/packages\/gnlm\/gnlm.pdf. Accessed 16 May 2024.","key":"901_CR18"},{"unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing;2018. Available from: https:\/\/www.R-project.org.","key":"901_CR19"},{"unstructured":"Hooker A. Model-based approaches as guidance to bioequivalence decision making: design and analysis considerations [Internet]. Sweden; Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/leveraging-quantitative-methods-and-modeling-modernize-generic-drug-development-and-review-public. Accessed 16 May 2024.","key":"901_CR20"},{"unstructured":"Hooker AC, Chen PX, Assawasuwannakit P, Karlsson MO. Improved bioequivalence assessment through model-informed and model-based strategies [Internet]. Sweden; Available from: https:\/\/www.fda.gov\/media\/138035\/download. Accessed 16 May 2024.","key":"901_CR21"},{"key":"901_CR22","doi-asserted-by":"publisher","DOI":"10.1023\/a:1011555016423","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB. Pharmacometrics evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001. https:\/\/doi.org\/10.1023\/a:1011555016423.","journal-title":"J Pharmacokinet Pharmacodyn"},{"unstructured":"Committee for medicinal products for human use. European medicines agency. Guideline on the investigation of bioequivalence. 2010;Vol. 1.","key":"901_CR23"},{"unstructured":"FDA. Guidance for industry bioavailability and bioequivalence studies for orally administered drug products\u2014general guidance for industry bioavailability and bioequivalence;2000.","key":"901_CR24"},{"issue":"2","key":"901_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cpt.1270","volume":"105","author":"C Seng Yue","year":"2019","unstructured":"Seng Yue C, Ozdin D, Selber-Hnatiw S, Ducharme MP. Opportunities and challenges related to the implementation of model-based bioequivalence criteria. Clin Pharmacol Ther. 2019;105(2):350\u201362. https:\/\/doi.org\/10.1002\/cpt.1270.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"901_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.clinthera.2017.04.005","volume":"84","author":"J Methaneethorn","year":"2018","unstructured":"Methaneethorn J. A systematic review of population pharmacokinetics of valproic acid. Br J Clin Pharmacol. 2018;84(5):816\u201334. https:\/\/doi.org\/10.1016\/j.clinthera.2017.04.005.","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00901-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00901-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00901-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T04:20:24Z","timestamp":1719289224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00901-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00901-8","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"19 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alejandra Schiavo: Conceptualization, Methodology, Software, Formal analysis, Investigation, Writing\u2014original draft, Visualization. Pietro Fagiolino: Conceptualization, Investigation, Writing\u2014review & editing. Marta V\u00e1zquez: Investigation, Writing\u2014review & editing. I\u00f1aki F. Troc\u00f3niz: Conceptualization, Methodology, Software, Writing\u2014review & editing. Manuel Ibarra: Conceptualization, Methodology, Software, Investigation, Formal analysis, Writing\u2014original draft, Visualization, Supervision, Project administration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This work was supported by the CAP (Comisi\u00f3n Acad\u00e9mica de Posgrado, UDELAR) with a grant to AS as a graduate student. PEDECIBA-Qu\u00edmica and CSIC (Comisi\u00f3n Sectorial de Investigaci\u00f3n Cient\u00edfica, UDELAR) granted funds to support AS Ph.D. studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The data that support the findings of this study are available from the corresponding author, MI, upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"All code implemented to perform the analyses contained in this work are available from the corresponding author, MI, upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors have no conflict of interest to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments). The protocol of the clinical study was previously approved by the Institutional Ethics Review Committee of Faculty of Chemistry (Universidad de la Rep\u00fablica, Uruguay). Resolution N\u00b0 101900-000425-09, June 4th, 2009.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All subjects enrolled in the study were previously informed of the protocol details and implications and gave their written informed consent prior to study inclusion.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}